Non-Dilutive Capital for Startups

Non-dilutive capital is money a company receives without giving up ownership: federal and state research awards, prizes, tax offsets, in-kind lab access, customer prepayments. No stock is sold, no board seat created, no liquidation preference stacked. The price is time, restriction, and compliance.

Current figures — verified 2026-08-11

Item	Value	Source
SBIR/STTR Phase I ceiling without an SBA waiver	$323,090	SBIR.gov
SBIR/STTR Phase II ceiling without an SBA waiver	$2,153,927	SBIR.gov
SBIR and STTR statutory authorization horizon	September 30, 2031	Pub. L. 119-83
Maximum research credit a qualified small business may elect against payroll taxes	$500,000 per year	IRS
Portion applied against employer Social Security tax	up to $250,000 per quarter, remainder against Medicare	IRS
Non-federal cost share qualifying a prototype other transaction	at least one third of total project cost	10 U.S.C. § 4022(d)
Single Audit trigger	$1,000,000 in federal awards expended per fiscal year	2 CFR 200.501

These figures change. Verify against the linked source before relying on them. Report an outdated figure

Key takeaways

• Non-dilutive capital costs no equity; it costs time, restriction, and reporting.
• The stack is wider than SBIR: prizes, other transactions, CRADAs, tax offsets.
• A federal laboratory may contribute facilities and staff but not cash.
• Grants work by funding prototypes, not by certifying quality to investors.
• Sequence non-dilutive money before the round it is meant to reprice.

What is non-dilutive capital for startups?

Non-dilutive capital is any funding that increases a company’s spending power without transferring ownership or control. The category includes federal and state research awards, prize competitions, tax credits and offsets, in-kind access to government laboratories, foundation research grants, and customer-funded development. Where each source sits relative to the others is mapped across the funding tracks hub.

Non-dilutive does not mean unconditional. Every instrument in the category carries strings, and the strings differ by type: restricted use and audit exposure on federal awards, publication or global-access covenants on foundation money, marking and reporting obligations on defense work, repayment obligations on recoverable grants and revenue-based financing. A royalty-bearing venture philanthropy deal touches no share of stock and can still constrain an exit more than a priced round would.

The useful mental model is a price list rather than a free-money list. Equity is priced in ownership and governance. Debt is priced in interest and covenants. Non-dilutive capital is priced in cycle time, allowable-cost rules, reporting cadence, eligibility constraints on the cap table, and the founder hours consumed in pursuit. The comparison across all capital types is developed in grants vs loans, equity, and contracts.

What are the main sources of non-dilutive capital?

Non-dilutive capital divides into five families, and the families behave differently enough that a strategy built for one fails in another. The table below compares the five on what they fund, who they fit, and what they demand.

Source family	What it funds	Who it fits	Principal cost
Federal research awards	Feasibility and development R&D	Deep-tech firms with a mission-aligned technology	Six to nine month cycles, compliance
Prizes and challenges	Results already achieved	Teams near a demonstrable milestone	No capital until you win
State and regional programs	Match, bridge, proposal preparation	Firms with a federal award or pending proposal	State-specific deadlines and residency
In-kind laboratory access	Instruments, facilities, staff time	Firms needing equipment they cannot buy	Negotiation time, no cash
Tax offsets and incentives	Privately funded R&D and hiring	Firms with payroll and qualifying research	Documentation, filing discipline

Two further sources sit at the boundary of the category and deserve naming. Revenue-based financing and venture debt take no equity at signing but create repayment obligations and, in the case of venture debt, usually warrants — genuinely dilutive in small measure and senior to common stock in a downside. Customer-funded development, where a design partner pays for the work that becomes your product, is the only source in the whole stack with no gatekeeper, no application, and no reporting beyond the contract.

How does federal research funding work as a capital source?

Federal research funding is the largest and most structured family of non-dilutive capital available to a startup, and the entry point for most companies is SBIR and STTR — set-aside programs that fund small business research and development in phases, with Phase I proving feasibility and Phase II funding the principal development effort. Mechanics, eligibility, and phase structure are covered in SBIR and STTR explained.

Two structural facts about SBIR and STTR shape planning. Award ceilings are set by the Small Business Administration and agencies may exceed them only by waiver, so budget to the agency’s published range rather than to the ceiling (SBIR.gov). And the programs are periodically reauthorized rather than permanent — the most recent reauthorization was signed as Public Law 119-83, extending both programs and their related pilots to a fixed statutory horizon (SBA).

Advanced research agencies operate on a different logic and write much larger checks. ARPA-E “funds and directs the research and development of advanced energy technologies,” bridging “the gap between outlier energy ideas and mass market adoption” (ARPA-E). ARPA-H “advances high-potential, high-impact biomedical and health research that cannot be readily accomplished through traditional research or commercial activity,” runs on term-limited program managers, and states its funding discipline plainly: “every milestone gates the next tranche” (ARPA-H). Programs are designed top-down, so the pursuit is a fit problem rather than an originality problem.

Other Transaction Authority makes defense and health innovation reachable for companies that cannot absorb procurement regulation. An other transaction is by definition not a contract, grant, or cooperative agreement, and therefore sits largely outside the Federal Acquisition Regulation. A prototype other transaction requires at least one qualifying condition — a nontraditional defense contractor or nonprofit research institution participating to a significant extent, all significant participants being small businesses or nontraditional contractors, a non-federal cost share, or a senior procurement executive determination (10 U.S.C. § 4022).

The commercially decisive provision is the follow-on: after a competitively selected prototype is successfully completed, a production award “may be awarded to the participants in the transaction without the use of competitive procedures.” The volume is not marginal — the Government Accountability Office found the Department of Defense obligated $62.9 billion through other transactions across fiscal years 2021 through 2024 (GAO-25-107546).

What non-dilutive capital exists outside federal research programs?

Outside federal research programs, four sources carry real weight for startups, and each has a different effort profile.

• Prize competitions. Every agency head “may carry out a program to award prizes competitively to stimulate innovation that has the potential to advance the mission of the respective agency” (15 U.S.C. § 3719). The statute also protects entrants: the federal government “may not gain an interest in intellectual property developed by a participant in a prize competition without the written consent of the participant.” Prizes pay on results, ask for no cost accounting, and provide no working capital before the win. Discovery is agency-by-agency rather than centralized.
• State innovation and match programs. States fund four archetypes: matching grants against a federal award, bridge funding between phases, pre-award or proposal-preparation money, and proposal labs with mentorship. Coverage is uneven and amounts vary widely by state (SSTI State SBIR/STTR Resource Guide). The pattern for finding yours: search your state’s economic development or commerce department for “SBIR match,” then check whether the state hosts a federally supported technology partnership program, which can often fund proposal assistance directly.
• Cooperative research and development agreements. A CRADA is an agreement under which a federal laboratory “provides personnel, services, facilities, equipment, intellectual property, or other resources with or without reimbursement (but not funds to non-Federal parties)” (15 U.S.C. § 3710a). The parenthetical is the whole point: a CRADA is in-kind capital, not cash. For a company that needs a beamline, a test range, or a materials characterization suite it cannot buy, that access is worth more than an equivalent grant.
• Economic development incentives. Job creation credits, investment credits, payroll withholding rebates, property tax abatements, and training grants subsidize hiring and facilities rather than research. Treated correctly, incentives are the layer that lowers burn rate, not the layer that funds the science.

Foundation and philanthropic research funding rounds out the set, particularly in disease-specific translational work that federal agencies deprioritize. Foundation awards carry no Bayh-Dole obligation and no federal registration burden, but they frequently cap indirect cost recovery well below a negotiated federal rate, which shifts real overhead onto the company. Rate mechanics are covered in indirect cost rates.

How do tax credits function as non-dilutive capital?

Tax credits function as non-dilutive capital by converting research spending a company has already made into cash it does not have to pay out. For a pre-revenue startup with no income tax liability, the mechanism that matters is the payroll-tax election: a qualified small business may elect to apply the research credit against employer payroll taxes rather than income tax, first against the employer share of Social Security tax up to a quarterly limit and then against the employer share of Medicare tax (IRS).

Two procedural details decide whether the money arrives. The election is made by completing the relevant portion of Form 6765 and attaching it “to the QSB’s timely filed (including extensions) income tax return” — it cannot be made on an amended return. The credit is then claimed on Form 8974, filed with the employment tax return. A company that misses the original filing has missed the year.

The interaction with federal research awards is where founders most often get it wrong. The research credit statute excludes funded research from qualified research expenses, and research funded by another person — including a governmental entity — falls in that exclusion. In broad terms, the award dollars a government paid you are not creditable, while privately funded research spending running alongside the award may be. The determination is fact-specific and turns on whether payment was contingent on success and whether the taxpayer retained substantial rights.

This section is general information about how the mechanism is structured, not tax advice. The credit and its funded-research exclusion are fact-intensive, and the analysis should be done with a tax professional against your actual contracts and books.

What does non-dilutive capital cost compared with equity?

Non-dilutive capital costs no ownership, and the arithmetic of the alternative is worth writing out because founders rarely do. Consider a company that needs $2 million to build and test a prototype.

Raising that $2 million in a priced round at an $8 million pre-money valuation produces a $10 million post-money, and the new investors hold 20 percent of the company. Add the terms that normally travel with the money: a liquidation preference sitting ahead of common stock, a board seat, and protective provisions over decisions the founders previously made alone. That 20 percent is not static — it dilutes further at every subsequent round and option pool refresh, and the preference stack sits ahead of common in every downside outcome.

Winning the same $2 million as a research award costs zero percent of the company, no board seat, no preference, and no protective provisions. The costs are real but different: cycle times commonly running six to nine months from submission to money, weeks of registration lead time before you can even apply, restrictions on what the money may buy, ownership and control rules that constrain the cap table, and reporting obligations that persist for years. Crossing the federal expenditure threshold adds an annual audit requirement on top (2 CFR 200.501), explained in the Single Audit.

The comparison that actually matters is neither of those. It is the third path: use non-dilutive money to build the prototype, then raise equity at the valuation the prototype supports. If the working prototype moves the pre-money from $8 million to $16 million, the same $2 million round buys about 11 percent instead of 20 percent. The non-dilutive award did not replace the equity round — it repriced it.

How should non-dilutive capital sequence with an equity raise?

Non-dilutive capital should be sequenced to buy the specific evidence that reprices the next round, and it should be started early enough that its cycle time does not collide with a cash need. Money that arrives in month nine does not solve a month-three shortfall, which is the single most common sequencing error.

A defensible order runs in six layers. Registration comes first and takes weeks, not days — see SAM.gov registration and the UEI. Feasibility funding comes second, at the smallest scale that produces a real technical result. State match applies on the same calendar as the federal proposal, not after the award. Development funding follows, sized to the prototype rather than to the ceiling. In-kind laboratory access and the research payroll credit run in parallel throughout, because neither competes with the others for the same application window. Equity comes last, timed against the artifact.

Two sequencing moves are legal and underused. A company may take a first-phase award at one agency and a second-phase award at another, which matters when the first agency’s budget runs dry. And bridge instruments at the late development stage increasingly require matching private or customer capital by design — meaning non-dilutive money at that stage is contingent on dilutive or commercial money, not a substitute for it.

What does grant funding signal to investors?

What grant funding signals to an investor is narrower than founders assume, and the evidence is specific. Sabrina Howell’s quasi-experimental study of ranked applicants to the Department of Energy’s SBIR program found that “an early-stage award approximately doubles the probability that a firm receives subsequent venture capital and has large, positive impacts on patenting and revenue,” with effects “stronger for more financially constrained firms.” Crucially, the study rejects the certification story:

“Certification, where the award contains information about firm quality, likely does not explain the grant effect. Instead, the grants are useful because they fund technology prototyping.” — Sabrina T. Howell, Financing Innovation: Evidence from R&D Grants, American Economic Review, 2017

The practical instruction follows directly. Lead an investor conversation with the artifact the award produced, not with the award. Portfolio-level outcomes support the pattern at scale — the Department of Energy reports that its 2009 to 2018 award cohort of 1,240 firms went on to raise $8.6 billion in private-sector follow-on funding and account for $4.6 billion in merger and acquisition activity (DOE Office of Science).

Investors also carry two legitimate concerns worth addressing before they raise them. The first is revenue quality: a company whose income is entirely government research money and whose customer list is empty reads as a research shop, not a business. The second is the cap table itself, because ownership and control rules in federal small business programs can be broken by a single investor taking majority ownership or blocking rights over ordinary business decisions. Governance terms should be checked against program eligibility before a term sheet is signed, not after.

When is chasing non-dilutive capital the wrong choice?

Chasing non-dilutive capital is the wrong choice when the pursuit cost exceeds the expected value, when the work proposed is not work you would otherwise do, or when the cash is needed sooner than the cycle can deliver it. A competitive first-phase proposal commonly consumes hundreds of hours of senior technical and executive time — the same hours that would otherwise go to selling, recruiting, and building.

Six conditions argue against pursuit:

• A cash need inside two quarters. Federal cycles run months. Grant funding is not a bridge.
• Reverse-engineering a project to fit a topic. Work invented to match a solicitation rarely survives contact with the roadmap.
• No commercial workstream left running. An award that consumes the entire technical team produces a report and no customers.
• Governance terms that break eligibility. A cap table or investor consent right that disqualifies the company converts a win into a liability.
• Award size below the administrative cost. Small awards carry the same compliance obligations as large ones.
• Concentration without traction. Award count is not the diagnostic. The diagnostic is whether non-award revenue and outside capital are growing year over year.

Concentration is a documented pattern rather than a hypothetical risk. An analysis of awards from 2009 through 2019 found that a small fraction of companies accounted for more than a fifth of all awards in the period, while roughly 41 percent of participating firms received exactly one award (SSTI). Optimizing for winning awards and optimizing for building a company are different objective functions, and they diverge quietly.

The reframe worth holding: non-dilutive capital buys evidence. Money that funds a working prototype, a completed pilot, or a regulatory milestone raises the terms on which every other kind of capital becomes available. Money that funds a report nobody was waiting for is capital spent on paperwork. Applying that test opportunity by opportunity is the discipline described in the go/no-go decision.

Frequently asked questions

Is non-dilutive capital the same as free money?

No. Non-dilutive capital is conditional money. Federal awards restrict use to the approved purpose, require documentation and reporting, and expose the recipient to disallowed costs and audit. Foundation and philanthropic instruments substitute their own conditions, including global-access covenants and royalty obligations that survive an acquisition.

Can a venture-backed startup still win federal research awards?

Sometimes, and the rules are specific. Federal small business programs impose ownership and control tests, and certain agencies have elected authority permitting majority ownership by multiple venture funds where no single fund holds a majority. Blocking rights over ordinary business decisions can independently create a control problem regardless of percentage.

What is the fastest form of non-dilutive capital?

Prize competitions and customer-funded development. Prizes pay on results with no cost accounting, though no capital arrives before the win (15 U.S.C. § 3719). A paying design partner is faster still, because the only gatekeeper is the customer.

Does a CRADA provide funding to the company?

No. A federal laboratory may contribute personnel, services, facilities, equipment, and intellectual property under a cooperative research and development agreement, but the statute explicitly excludes providing funds to non-federal parties (15 U.S.C. § 3710a). The value is access, and the partner may contribute funds in the other direction.

How long does non-dilutive capital take to arrive?

Plan in quarters. Federal research awards commonly run six to nine months from submission to first payment, on top of weeks of registration lead time. State match programs run on their own calendars, frequently first-come. Tax offsets arrive on the payroll filing cycle after the return is filed.

Should a startup hire someone to pursue non-dilutive capital?

That depends on volume and fit. A single opportunity rarely justifies a hire; a repeatable pipeline across multiple agencies and states sometimes does. The threshold question is whether the work you would propose is work the company would do anyway.

Related topics

• Funding Tracks by Funder Type — the hub for how each funding track behaves
• SBIR and STTR Explained
• Research Grants at NIH and NSF
• Grants vs Contracts vs Cooperative Agreements
• Building a Grant Pipeline

Sources

1. U.S. Small Business Administration. About SBIR and STTR. SBIR.gov. https://www.sbir.gov/about (accessed 2026-08-11)
2. U.S. Congress. Public Law 119-83, Small Business Innovation and Economic Security Act. https://www.congress.gov/119/plaws/publ83/PLAW-119publ83.pdf (accessed 2026-08-11)
3. U.S. Small Business Administration. Administrator Loeffler Applauds SBIR-STTR Reauthorization. April 13, 2026. https://www.sba.gov/article/2026/04/13/administrator-loeffler-applauds-sbir-sttr-reauthorization (accessed 2026-08-11)
4. U.S. Code. 10 U.S.C. § 4022 — Authority of the Department of Defense to carry out certain prototype projects. Legal Information Institute, Cornell Law School. https://www.law.cornell.edu/uscode/text/10/4022 (accessed 2026-08-11)
5. U.S. Code. 15 U.S.C. § 3719 — Prize competitions. Legal Information Institute, Cornell Law School. https://www.law.cornell.edu/uscode/text/15/3719 (accessed 2026-08-11)
6. U.S. Code. 15 U.S.C. § 3710a — Cooperative research and development agreements. Legal Information Institute, Cornell Law School. https://www.law.cornell.edu/uscode/text/15/3710a (accessed 2026-08-11)
7. U.S. Government Accountability Office. Other Transactions: DOD Obligations and Use of Authority. GAO-25-107546, September 3, 2025. https://files.gao.gov/reports/GAO-25-107546/index.html (accessed 2026-08-11)
8. Internal Revenue Service. Qualified small business payroll tax credit for increasing research activities. https://www.irs.gov/businesses/small-businesses-self-employed/qualified-small-business-payroll-tax-credit-for-increasing-research-activities (accessed 2026-08-11)
9. Office of Management and Budget. 2 CFR 200.501 — Audit requirements. eCFR. https://www.ecfr.gov/current/title-2/section-200.501 (accessed 2026-08-11)
10. Advanced Research Projects Agency–Energy. History. U.S. Department of Energy. https://arpa-e.energy.gov/about/arpa-e-history (accessed 2026-08-11)
11. Advanced Research Projects Agency for Health. About Us. https://arpa-h.gov/about (accessed 2026-08-11)
12. U.S. Department of Energy, Office of Science. SBIR/STTR Evaluation and Program Outcomes. https://science.osti.gov/sbir/Evaluation (accessed 2026-08-11)
13. Howell, S. T. Financing Innovation: Evidence from R&D Grants. American Economic Review 107(4): 1136–1164, 2017. https://www.aeaweb.org/articles?id=10.1257%2Faer.20150808 (accessed 2026-08-11)
14. SSTI. State SBIR/STTR Resource Guide. https://ssti.org/state-sbirsttr-resource-guide (accessed 2026-08-11)
15. SSTI. SSTI analysis reveals SBIR mills take outsized portion of programs’ awards. https://ssti.org/blog/ssti-analysis-reveals-sbir-mills-take-outsized-portion-programs-awards (accessed 2026-08-11)